Disclosed is a process for the production of acids of the formula ##STR1## wherein R is 2-fluoro-4-(1,1'-biphenyl), 4-(2-methylpropyl)phenyl, 6-methoxy-2-napthyl, 3-benzophenyl, 4-(2-thienylcarbonyl)-phenyl or 7-chlorocarbazole-3-yl which comprises contacting an organometallic compound of the formula R--M--R.sub.1 (G) with an allyl halide of the formula ##STR2## to produce an olefin of the formula ##STR3## ozonolysis of the olefin (II) to produce an aldehyde of the formula ##STR4## which is oxid...

A transdermal drag delivery device involving an acrylate or methacrylate based copolymer, a skin penetration enhancer, a polyvinylpyrrolidone polymer, and a therapeutically effective amount of flurbiprofen.

Pharmaceutical compositions of nalbuphine and flurbiprofen have been found to exhibit unexpectedly enhanced analgesic activity by applying an analysis model which considers data characterizing the analgesic effect of both the pure components as well as the fixed dose ratio combinations. This synergism enables the use of lower doses of either or both drugs with a concomitant reduction in risk of possible side effects.

There is provided an ophthalmic preparation comprising a fat emulsion containing flurbiprofen or its derivative such as ester as an active ingredient.

A process producing a pharmaceutical lozenge formulation comprising the steps of: 1) granulating a mixture of flurbiprofen and a bulking agent with a solution of a binding agent in a polar solvent to form granules; 2) melting a lozenge-forming composition; 3) mixing the granules with the molten lozenge-forming composition; 4) forming the resulting mixture into lozenges each containing a therapeutically effective amount of flurbiprofen.

This invention relates to the use of sugar-based or sugar alcohol-based lozenges containing flurbiprofen for the treatment of sore throat.

The present invention provides a method for producing optically active flurbiprofen. The method of the present invention includes mixing racemic flurbiprofen and (S)- or (R)-3-methyl-2-phenylbutylamine in an organic solvent to produce a diastereomeric salt; and treating the diastereomeric salt with an acid in a second solvent. In the method of the present invention, flurbiprofen having a desired absolute configuration can be obtained very efficiently without repeating the procedure for optical r...

There is provided a fat emulsion of an ester of flurbiprofen having the formula ##STR1## wherein R is a group of the formula ##STR2## wherein R.sub.1 is a hydrogen atom or a C.sub.1 -C.sub.3 alkyl group, R.sub.2 is a C.sub.1 -C.sub.15 alkyl group or a C.sub.2 -C.sub.8 alkenyl group, and m is zero or an integer of 1; or a lactone group of the formula ##STR3## wherein R.sub.3 and R.sub.4 are same as or different from each other and are a hydrogen atom or a C.sub.1 -C.sub.3 alkyl group, and n is an...

A method of treating vascularization of the eye as a result of traumatic injury, surgery, such as, corneal transplant, or onset of diabetic retinopathy by topically treating the eye with Flurbiprofen or a pharmaceutically acceptable salt thereof.

Disclosed are ophthalmic pharmaceutical compositions comprising S(+)-flurbiprofen substantially free of R(+)-flurbiprofen and methods of topical administration to the eye when indicated for treatment of inflammation.